Emerging clinical observations are reporting neurological complications associated with treatment using anti-CTLA-4 and anti-PD-1 [17, 19, 37] in patients with melanoma, lung cancers, and Merkel-cell carcinoma at five weeks post-therapy [17]. This evidence concerns the gene PDCD1 and lung carcinoma.